198 related articles for article (PubMed ID: 24434330)
1. Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells.
Rana D; Chawla Y; Arora SK
Indian J Med Res; 2013 Nov; 138(5):766-78. PubMed ID: 24434330
[TBL] [Abstract][Full Text] [Related]
2. Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment.
Rana D; Chawla YK; Duseja A; Dhiman R; Arora SK
Liver Int; 2012 Aug; 32(7):1128-37. PubMed ID: 22309109
[TBL] [Abstract][Full Text] [Related]
3. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
Todorovska B; Joksimovic N; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Curakova E; Kiprijanovska S; Zafirova-Ivanovska B; Serafimoski V
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):25-33. PubMed ID: 28593897
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.
Kanto T; Inoue M; Oze T; Miyazaki M; Sakakibara M; Kakita N; Matsubara T; Higashitani K; Hagiwara H; Iio S; Katayama K; Mita E; Kasahara A; Hiramatsu N; Takehara T; Hayashi N
J Gastroenterol; 2012 Feb; 47(2):169-78. PubMed ID: 21947705
[TBL] [Abstract][Full Text] [Related]
5. Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
Lee JW; Kim W; Kwon EK; Kim Y; Shin HM; Kim DH; Min CK; Choi JY; Lee WW; Choi MS; Kim BG; Cho NH
PLoS One; 2017; 12(6):e0179094. PubMed ID: 28614389
[TBL] [Abstract][Full Text] [Related]
6. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
Jessner W; Stauber R; Hackl F; Datz C; Watkins-Riedel T; Hofer H; Gangl A; Kessler H; Ferenci P
J Viral Hepat; 2003 Jan; 10(1):37-42. PubMed ID: 12558910
[TBL] [Abstract][Full Text] [Related]
7. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.
Baur K; Mertens JC; Schmitt J; Iwata R; Stieger B; Frei P; Seifert B; Bischoff Ferrari HA; von Eckardstein A; Müllhaupt B; Geier A;
Antivir Ther; 2012; 17(3):541-7. PubMed ID: 22300961
[TBL] [Abstract][Full Text] [Related]
8. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
[TBL] [Abstract][Full Text] [Related]
9. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
[TBL] [Abstract][Full Text] [Related]
11. Toll like receptor 3 expression as a novel predictor of response to treatment in chronic hepatitis C virus patients.
Hashad DI; Salem PE; Abdallah DM
Scand J Clin Lab Invest; 2011 Dec; 71(8):641-6. PubMed ID: 22023039
[TBL] [Abstract][Full Text] [Related]
12. Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries.
Ceylan B; Arslan F; Yardimci C; Fincanci M; Özgüneş N
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):493-4. PubMed ID: 24598385
[No Abstract] [Full Text] [Related]
13. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
[TBL] [Abstract][Full Text] [Related]
14. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Iio S; Oshita M; Hagiwara H; Mita E; Inui Y; Hijioka T; Inada M; Tamura S; Yoshihara H; Inoue A; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Hayashi N; Takehara T
J Gastroenterol; 2014 Apr; 49(4):737-47. PubMed ID: 23689988
[TBL] [Abstract][Full Text] [Related]
15. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
16. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H
J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.
Asselah T; Estrabaud E; Bieche I; Lapalus M; De Muynck S; Vidaud M; Saadoun D; Soumelis V; Marcellin P
Liver Int; 2010 Oct; 30(9):1259-69. PubMed ID: 20633102
[TBL] [Abstract][Full Text] [Related]
18. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C.
Crosignani A; Riva A; Della Bella S
World J Gastroenterol; 2016 Jan; 22(4):1393-404. PubMed ID: 26819508
[TBL] [Abstract][Full Text] [Related]
19. Sustained virological response after 4 weeks of telaprevir, peginterferon, and ribavirin in an Asian patient with genotype 1 chronic hepatitis C and IL28B genotype CC.
Brulotte N; Hahn H; Lee M
Dig Dis Sci; 2014 Apr; 59(4):737-9. PubMed ID: 24114049
[No Abstract] [Full Text] [Related]
20. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
